We are delighted to announce the appointment of the new Head of the CRO business area Ulrika Hammarström. She assumes the CRO business area head position in Aurevia and will lead the international Aurevia CRO (Contract Research Organization) team. Aurevia has professional CRO teams in Sweden, Poland, Germany, and Finland.
Ulrika is a member of the Aurevia Management team, and she reports to Aurevia CEO Juha-Pekka Nuutinen. Aurevia’s CRO team offers international clinical trial services for pharmaceutical, biotech, and medical device companies, as well as academia.
Ulrika holds a Master of Science in Molecular Biology and a postgraduate qualification in Clinical Drug Development from Uppsala University. She has worked in the CRO business since 2001 and has extensive experience in various roles, including CRA manager, Clinical Project Leader, and Country Manager. She is also the Founder and CEO of Scandinavian CRO in Sweden. In 2024, Ulrika was chosen as the local and regional Entrepreneur of the Year, as well as an EY Entrepreneur of the Year Finalist at the national level. In August 2024, Aurevia acquired Scandinavian CRO.
“It is my pleasure to welcome Ulrika to the Aurevia team. She will contribute to Aurevia’s CRO business development and growth with her solid leadership experience and knowledge of CRO operations. Ulrika will build and strengthen our CRO offering and geographical coverage to position Aurevia as the full-service European CRO provider. Additionally, we share the same passion for quality excellence in healthcare,” says CEO Juha-Pekka Nuutinen from Aurevia.
“I’m thrilled to join the Aurevia team and look forward to expanding our CRO business. Our team of highly skilled experts have decades of experience working in clinical research, and together with our quality assurance and regulatory affairs (QARA) colleagues, we can support our clients throughout their product development lifecycle. Ultimately, the goal is to provide patients with better outcomes and quality of life,” concludes Ulrika Hammarström.
Ulrika started in her new role on January 1, 2025. Her first milestone is to develop and build Aurevia’s new CRO organization and operations.
For queries, please contact:
Juha-Pekka Nuutinen
CEO | Aurevia
+358 40 828 3210 | juha-pekka.nuutinen@aurevia.com
AUREVIA
As Aurevians, we are the excellence makers: a team of experienced experts in healthcare and health-tech standards and quality. Together, we advance healthcare, pharmaceutical and medical technology development with a future-focused approach, aligned with client needs. Driven by our commitment to care, we contribute quality to the industry and pave the way for safer, more effective patient care worldwide.
We are a full-service, rapid-response Contract Research Organization (CRO) and external quality assessment services (EQAS) provider. Our quality services for the healthcare, pharmaceutical, and medical technology industries cover external quality assessments, quality assurance, regulatory affairs, clinical investigations and trials, audits and certifications, and training. Our expertise and knowledge benefit medical device and in vitro diagnostic manufacturers, pharmaceutical companies, healthcare units, and clinical laboratories.
Currently, we serve over 8000 customers in over 60 countries around the world. Our team comprises nearly 200 skilled professionals in offices in Finland, Sweden, Poland, and Germany. Aurevia is supported by Mérieux Equity Partners.
Aurevia – empowering clients with excellence-driven solutions to achieve the highest standards in patient care.
Share this article
